CPT 81239 DMPK Testing Reimbursement & Policy

CPT code 81239 represents a specialized genetic laboratory procedure to further characterize abnormalities in the DMPK (DM1 protein kinase) gene, typically by measuring nucleotide repeat expansions or assessing methylation status. This code is important nationally because accurate molecular characterization of DMPK variants informs diagnosis, prognosis, and genetic counseling for myotonic dystrophy type 1 and related conditions. Payers commonly involved in coverage and reimbursement for this service include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn the clinical context for CPT code 81239, including how the assay fits into the diagnostic pathway following an initial abnormal result. The publication covers service setting expectations, common billing modifiers, and workflow considerations relevant to laboratories and billing teams. It also provides benchmarks and policy-relevant summaries to help stakeholders understand typical utilization patterns, payer scope, and documentation elements needed to support medical necessity. Data not available in the input is noted where relevant.

Billing Code Overview

CPT code 81239 describes a laboratory molecular characterization test for the DMPK (DM1 protein kinase) gene. The procedure involves technical laboratory analysis to define nucleotide repeat length or methylation status after an initial abnormality has been detected, providing more detailed genetic information for diagnostic and management purposes.

Service Type: Genetic molecular diagnostic testing

Typical Site of Service: Clinical diagnostic laboratory (reference or specialty molecular lab)

Clinical Context

A typical scenario involves an adult or pediatric patient with a clinical suspicion or prior laboratory result indicative of myotonic dystrophy type 1 (DM1). A neurologist or geneticist orders molecular testing after an initial screening test (for example, repeat-primed PCR or Southern blot) shows an abnormality in the DMPK gene repeat region or ambiguous sizing/methylation. The specimen (blood or extracted DNA) is sent to a clinical molecular laboratory. A laboratory technologist or molecular analyst performs specialized characterization to define the number of CTG trinucleotide repeats, assess repeat expansion size, and determine methylation status when required. Results support diagnostic confirmation, prognosis (anticipation and correlation with disease severity), reproductive counseling, and family testing. Typical workflow steps: sample accessioning, DNA extraction verification, performance of repeat-primed PCR and/or Southern blot (or other sizing method), analysis of methylation assays if indicated, result interpretation by molecular pathologist, and reporting to the ordering clinician. Typical site of service is a clinical reference or hospital-based molecular diagnostic laboratory; specimen collection typically occurs in an outpatient clinic or hospital phlebotomy service.

Coding Specifications

Modifier	Description	When to Use
`11`	Office or other outpatient service (standard)	Use when billing reflects the routine professional service component for the ordering or interpreting clinician.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Clinical Molecular Genetics Laboratory	Primary laboratory specialty performing molecular diagnostics for DMPK testing.
`207K00000X`	Clinical Laboratory	General laboratory specialty that may perform technical components in hospital labs.
`2084P0800X`	Neurology	Ordering specialty; neurologists commonly order confirmatory DMPK testing for suspected DM1.
`208D00000X`	Medical Genetics	Medical geneticists and genetic counselors interpret results and provide counseling.
`207LP2901X`	Pathology - Molecular	Molecular pathologists review assay validation, interpretation, and reporting.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`G71.11`	Myotonic dystrophy	Primary diagnosis indicating DM1; DMPK testing confirms molecular diagnosis and informs prognosis.
`R94.8`	Abnormal results of function studies of other specified body systems	Used when prior screening tests are abnormal and further molecular characterization is required.
`Z13.79`	Encounter for screening for other disorder	May be used for family screening or cascade testing when there is known family history.
`Z15.89`	Genetic susceptibility to other disease	Used when patient has family history of a known DMPK pathogenic expansion and requires predictive testing.
`R53.1`	Weakness	Common clinical symptom prompting neurologic evaluation and subsequent genetic testing for myotonic dystrophy.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81239`	The lab analyst performs the technical lab test to characterize changes in the DM1 protein kinase gene (DMPK), typically to further define nucleotide repeats or methylation status following detection of an abnormality.	Primary molecular characterization code for detailed sizing/methylation analysis after an abnormal screening result.
`81240`	Analysis of DMPK gene; targeted mutation analysis or sizing of trinucleotide repeat expansions.	Often performed as an initial or complementary assay to determine repeat size; may precede or be combined with `81239` depending on findings.
`88271`	Southern blot for genetic testing (per probe)	Historical method for sizing large CTG expansions and assessing methylation; sometimes used in conjunction with modern assays when large expansions cannot be sized by PCR alone.
`81479`	Unlisted molecular pathology procedure	Used when a specific, contractually unique, or newly developed assay for DMPK characterization does not map precisely to existing CPT codes; billed only with appropriate documentation.
`G0452`	Pharmacogenomic testing (Medicare-specific)	May be used in related genetic testing contexts under Medicare policies; not typically the primary code for DMPK characterization but appears in broader molecular testing workflows.

OpenPayer

Summary & Overview

CPT 81239: DMPK Gene Repeat and Methylation Characterization